Navigation Links
Citi Private Equity Executive Joins Water Street Healthcare Partners
Date:5/29/2009

ted with Water Street's team over the years, I've appreciated their deep expertise and unique investment approach. The results that Water Street has achieved in three years since raising its first fund speak volumes to the effectiveness of the strategy. I am thrilled to become a member of the team, and play an active role in future investments and growth."

Since raising its first fund in 2006, Water Street has completed 16 investments and built 10 leading health care companies. During the same time period, it has more than doubled the size of its team. The firm recently announced that it closed its eighth acquisition in the past 10 months.

"A number of trends including aging demographics, technology advancements and a shift toward consumerism continue to drive growth in health care," said Dugan. "In today's challenging economic environment, we continue to uncover unique opportunities for investments. With the addition of Rob and other senior hires this year, we are very well-positioned to capitalize on our strong and active pipeline. Our focus will be investing in those companies that offer the strongest foundations for expansion in attractive segments of health care."

Water Street is currently pursuing investments in six segments of health care: diagnostic devices, medical products, pharmaceutical services, specialty distribution, specialty pharmaceuticals and specialty services. Its transactions typically range from $50 million to $500 million in value.

About Water Street Healthcare Partners

Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. The firm has a strong record of building market-leadership companies across key growth sectors in health care. It has partnered with so
'/>"/>

SOURCE Water Street Healthcare Partners
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Womens Digital Imaging of Ridgewood First Private Medical Practice in New York Area to Screen With Breast Specific Gamma Imaging (BSGI)
2. Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages
3. MIT is pleased to announce that it has received a US$ 200,000 private placement from its future Chinese partners
4. Neovasc Completes $2 Million Non-Brokered Private Placement
5. Pharmos Completes Private Placement - Raises $1.8 Million
6. Good News for Tough Times: Small, Private University Responds to Todays Economic Challenges
7. HBA Global Expo Platforms Private Label/Contract Manufacturing
8. Barry Arbuckle, MemorialCare Medical Center CEO and California Hospital Association Past Chair, Speaks Out on Impact of 3-Year, $32 Million Public-Private Partnership
9. Private-label OTC Drugs Post Solid Gains in 2008, According to Kline
10. Neovasc to Raise $2 Million in Non-Brokered Private Placement
11. Clarient Entered Into Private Placement of Up To $50 Million in Convertible Preferred Stock With Oak Investment Partners
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 1HemCon Medical Technologies Inc signs exclusive global agreement with Zimmer Dental Inc to distribute oral surgery dressings 57154 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 1Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 2Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 3Eat Healthy Helps Parents Make Every Bite Fast Frugal Fun and Eco Friendly 57151 4Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 1Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 2Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 3Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes 5004 4